Calls
4
Eric Lefkofsky
Founder and CEO, Tempus AI; Managing Partner, Lightbank Capital
Win Rate
25.0%
return
-0.1%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 14
$145.36
-0.6%
Merck and Moderna's personalized cancer vaccine is a major example of moving from targeted to personalized therapies: sequencing a patient and building a drug based on that person's unique molecular and immune profile could make immunotherapies effective in patients who do not respond. The trial success was dramatic, and the companies have suggested more readouts are coming, supporting excitement across the space.
Pharma & Biotech
Long
Sep 14
$145.74
+0.4%
Merck and Moderna's personalized cancer vaccine is a major example of moving from targeted to personalized therapies: sequencing a patient and building a drug based on that person's unique molecular and immune profile could make immunotherapies effective in patients who do not respond. The trial success was dramatic, and the companies have suggested more readouts are coming, supporting excitement across the space.
Pharma & Biotech
Long
Sep 14
$62.24
-0.3%
Tempus AI has two core businesses—diagnostics and data—that use large datasets and AI to make diagnostics smarter and help drug companies develop better drugs. The company has amassed a large dataset, and frontier models were perfectly designed to help both businesses, with Tempus actively scaling these models for the past three to four years.
Diagnostics
Long
Sep 14
$167.71
-0.0%
Healthcare is likely to be the biggest eventual beneficiary of AI because frontier models are especially good at making sense of unstructured, disparate, and messy healthcare data, and the application—helping people live longer and healthier lives—is highly valuable.
Thematic ETFs
Showing 4 of 4 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Eric Lefkofsky has 4 trade ideas tracked on Buzzberg across 4 tickers since September 2026. Most covered: MRK, XLV, MRNA.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
